Titan Pharmaceuticals, Inc. (TTNP)
Stock Price:
$0.309 USD
0.009 (3.13%)
Updated Aug 10, 2020 2:04 PM EDT - Market closed
Key Info
| Market Cap |
29.60M |
| Revenue (ttm) |
4.00M |
| Net Income (ttm) |
-17.53M |
| Shares Out |
95.66M |
| EPS (ttm) |
-0.44 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 10, 2020 |
| Last Price |
$0.309 |
| Previous Close |
$0.300 |
| Change ($) |
0.009 |
| Change (%) |
3.13% |
| Day's Open |
0.304 |
| Day's Range |
0.297 - 0.318 |
| Day's Volume |
4,921,605 |
| 52-Week Range |
0.142 - 0.789 |
More Stats
| Market Cap |
29.60M |
| Enterprise Value |
26.08M |
| Earnings Date (est) |
Aug 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
95.66M |
| Float |
95.38M |
| EPS (basic) |
-0.46 |
| EPS (diluted) |
-0.44 |
| FCF / Share |
-0.20 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
7.67M |
| Short Ratio |
0.67 |
| Short % of Float |
7.77% |
| Beta |
0.90 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
7.40 |
| PB Ratio |
5.45 |
| Revenue |
4.00M |
| Operating Income |
-16.79M |
| Net Income |
-17.53M |
| Free Cash Flow |
-16.59M |
| Net Cash |
3.51M |
| Net Cash / Share |
0.04 |
| Gross Margin |
-122.91% |
| Operating Margin |
-419.42% |
| Profit Margin |
-437.90% |
| FCF Margin |
-414.57% |
| ROA |
-84.94% |
| ROE |
-420.72% |
| ROIC |
-324.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$0.90*
(190.89% upside)
Low
0.80
Current: $0.309
High
1.00
Target: 0.90
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 3.61 | 6.62 | 0.22 | 15.07 | 1.67 | 3.65 | 10.48 | 7.12 | 4.07 | 10.09 |
| Revenue Growth | -45.44% | 2978.14% | -98.57% | 801.56% | -54.17% | -65.21% | 47.27% | 74.95% | -59.69% | - |
| Gross Profit | 2.32 | 6.08 | 0.22 | 15.07 | 1.67 | 3.65 | 10.48 | 7.12 | 4.07 | 10.09 |
| Operating Income | -16.84 | -8.26 | -14.50 | 4.34 | -6.76 | -3.48 | -0.89 | -8.37 | -10.51 | -6.03 |
| Net Income | -16.46 | -9.02 | -14.31 | 5.14 | -11.28 | -2.40 | 9.71 | -15.18 | -15.20 | -6.83 |
| Shares Outstanding | 22.96 | 5.69 | 3.53 | 3.46 | 3.34 | 2.84 | 2.49 | 2.01 | 1.79 | 1.79 |
| Earnings Per Share | -0.72 | -1.66 | -4.22 | 1.20 | -3.36 | -1.20 | 3.18 | -7.62 | -9.28 | -2.98 |
| Operating Cash Flow | -15.45 | -8.43 | -12.68 | 6.29 | -7.47 | -5.87 | -9.80 | 1.83 | -14.48 | -4.66 |
| Capital Expenditures | -0.26 | -0.42 | -0.18 | -0.17 | -0.13 | -0.02 | -0.32 | -1.15 | -0.23 | -0.03 |
| Free Cash Flow | -15.70 | -8.85 | -12.85 | 6.12 | -7.60 | -5.88 | -10.12 | 0.68 | -14.71 | -4.69 |
| Cash & Equivalents | 5.22 | 9.66 | 7.88 | 14.01 | 7.86 | 15.47 | 11.80 | 18.10 | 5.41 | 3.18 |
| Total Debt | 4.44 | 4.31 | 6.58 | - | - | - | - | 11.86 | 12.25 | 7.27 |
| Net Cash / Debt | 0.78 | 5.34 | 1.30 | 14.01 | 7.86 | 15.47 | 11.80 | 6.24 | -6.85 | -4.09 |
| Assets | 9.52 | 14.10 | 8.91 | 18.67 | 13.29 | 20.85 | 18.42 | 24.83 | 10.22 | 4.75 |
| Liabilities | 8.09 | 7.26 | 8.05 | 5.48 | 6.30 | 12.24 | 12.66 | 47.96 | 30.30 | 10.81 |
| Book Value | 1.43 | 6.83 | 0.86 | 13.19 | 6.99 | 8.61 | 5.76 | -23.13 | -20.08 | -6.05 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Titan Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
21 |
| CEO |
Sunil Bhonsle |
Stock Information
| Ticker Symbol |
TTNP |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: TTNP |
| IPO Date |
January 18, 1996 |
Description
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction in patients. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.